Bial-Portela & CA, S.A., and Eisai Europe Limited, the European subsidiary of Eisai Co., Ltd. today announced that the novel once dailyanti-epileptic Zebinix(R) (eslicarbazepine acetate) received marketingauthorisation from the European Commission as adjunctive therapy in adultswith partial-onset seizures, with or without secondary generalisation.
the details can be read here.
No comments:
Post a Comment